View all news

    ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    05/31/2019
    Download(opens in new window)PDF 225 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com